• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFA14A filed by Dare Bioscience Inc.

    6/1/26 8:59:59 AM ET
    $DARE
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $DARE alert in real time by email
    DEFA14A 1 formdefa14a.htm DEFA14A

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 14A

     

    PROXY STATEMENT PURSUANT TO SECTION 14(A) OF THE

    SECURITIES EXCHANGE ACT OF 1934

     

     

    Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐
           
    Check the appropriate box:  
           
    ☐   Preliminary Proxy Statement  
         
    ☐   Confidential, for Use of the Commission only (as permitted by Rule 14a-6(e)(2))
         
    ☐   Definitive Proxy Statement  
         
    ☒   Definitive Additional Materials  
         
    ☐   Soliciting Material under § 240.14a-12

     

    DARÉ BIOSCIENCE, INC.

     

    (Name of Registrant as Specified In Its Charter)

     

     

     

    (Name of Person(s) Filing Proxy Statement if Other Than the Registrant)

     

    Payment of Filing Fee (Check all boxes that apply):

     

    ☒   No fee required
    ☐   Fee paid previously with preliminary materials
    ☐   Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11

     

     

     

     
     

     

    Daré Bioscience, Inc. may post one or more of the following messages on various social media platforms, including LinkedIn, Facebook, X, Instagram and TikTok, from time to time beginning on June 1, 2026:

     

    Post 1

     

    Your vote takes less time than this post will take to read.

     

    Daré Bioscience’s (Nasdaq: DARE) 2026 Annual Meeting of Stockholders is June 11. If you own shares, you can vote right now — it can take under five minutes.

     

    Vote online at proxyvote.com using the control number on your proxy card or Notice of Internet Availability.

     

    One thing that catches people: if your shares are held through a broker, bank or similar organization, that organization will not automatically vote your shares on all matters being submitted for a vote. If you want your shares to be voted on all matters, you have to give voting instructions to that organization, and the deadline for receiving your instructions is likely earlier than June 11.

     

    The Notice for the Annual Meeting and the related Proxy Statement and Form 10-K are all at proxyvote.com. Meeting is virtual: virtualshareholdermeeting.com/DARE2026

     

    #DaréBioscience #DARE #WomensHealth #AnnualMeeting #ShareholderVote

     

    Post 2

     

    Four days left to vote.

     

    Daré Bioscience’s (Nasdaq: DARE) Annual Meeting of Stockholders is June 11. If you haven’t voted your shares yet, now’s the time.

     

    Vote in minutes at proxyvote.com, or by phone at 1-800-690-6903. Your control number is on your proxy card or Notice of Internet Availability.

     

    Holding shares through a broker, bank or similar organization? If you want your shares to be voted on all matters being submitted for a vote, you’ll need to give voting instructions to that organization — and check their deadline for receiving your instructions, which is likely before June 11.

     

    Every vote counts. Thank you for being part of Daré Bioscience.

     

    The Notice for the Annual Meeting and the related Proxy Statement and Form 10-K are all at proxyvote.com. Meeting is virtual: virtualshareholdermeeting.com/DARE2026

     

    #DaréBioscience #DARE #WomensHealth #AnnualMeeting

     

     
     

     

    Post 3

     

    Your 30-second reminder if you own Daré Bioscience stock

     

    Our 2026 Annual Meeting of Stockholders is June 11. Voting can take under five minutes — head to proxyvote.com and use the control number on your proxy card or Notice of Internet Availability.

     

    One thing that trips people up: if you hold shares through a broker, bank or similar organization, you have to give voting instructions to that organization to have your shares voted on all matters being submitted for a vote, and their deadline for receiving your instructions is likely before June 11.

     

    Link in bio. Daré Bioscience (Nasdaq: DARE).

     

    The Notice for the Annual Meeting and the related Proxy Statement and Form 10-K are all at proxyvote.com. Meeting is virtual: virtualshareholdermeeting.com/DARE2026

     

    #DaréBioscience #DARE #WomensHealth #AnnualMeeting #ShareholderVote

     

    Post 4

     

    Four days left to vote your Daré shares.

     

    The Daré Bioscience (Nasdaq: DARE) Annual Meeting of Stockholders is June 11. If you haven’t voted yet, it takes minutes — proxyvote.com or call 1-800-690-6903. Your control number is on your proxy card or Notice of Internet Availability.

     

    Holding your shares through a broker, bank or similar organization? Give your voting instructions to them, and check their deadline for receiving your instructions — it is likely earlier than June 11.

     

    Every vote counts. Link in bio.

     

    The Notice for the Annual Meeting and the related Proxy Statement and Form 10-K are all at proxyvote.com. Meeting is virtual: virtualshareholdermeeting.com/DARE2026

     

    #DaréBioscience #DARE #WomensHealth #AnnualMeeting

     

     

     

    Get the next $DARE alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $DARE

    DatePrice TargetRatingAnalyst
    6/30/2021$9.00 → $11.00Buy
    Roth Capital
    More analyst ratings

    $DARE
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Roth Capital reiterated coverage on Dare Bioscience with a new price target

    Roth Capital reiterated coverage of Dare Bioscience with a rating of Buy and set a new price target of $11.00 from $9.00 previously

    6/30/21 9:55:24 AM ET
    $DARE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $DARE
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Daré Bioscience Announces the Upcoming Launch of Flora Sync LF5™ Vaginal Probiotic Capsules

    First Product Revenue Expected This Month, Opening New Commercial Chapter for Women's Health Innovator Limited-Time Launch Offer: 30% Off + Free Shipping SAN DIEGO, June 04, 2026 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE), a purpose-driven health biotech company solely focused on closing the gap in women's health between promising science and real-world solutions, today announced the upcoming commercial launch of Flora Sync LF5™, a vaginal probiotic capsule formulated specifically to restore microbiome balance and support lasting vaginal comfort. The launch represents a milestone for Daré, as the company expects to generate its first direct consumer product revenue in June

    6/4/26 8:00:00 AM ET
    $DARE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Daré Bioscience Receives NIH Funding Award Notice to Advance DARE-HPV, its Novel Investigational Treatment for Persistent High-Risk HPV Infection, the Most Common Cause of Cervical Cancer

    Receipt of award notice for second $1.0 million tranche of NIAID funding brings total NIH funding award for DARE-HPV to $2.0 millionFunding award milestone follows Daré's announcement last week of the initiation of its Phase 2 clinical study of DARE-HPV — representing the first time women with persistent high-risk HPV infection may have access to this pharmacologic treatment as part of a clinical trialDARE-HPV targets high-risk HPV infection, the cause of virtually all cervical cancer cases in the U.S., for which there are currently no FDA-approved pharmacologic treatmentsAward reflects Daré's strategy of leveraging non-dilutive government funding, including both NIH grants and ARPA-H contra

    5/26/26 8:00:00 AM ET
    $DARE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Daré Bioscience Initiates Phase 2 Study of DARE-HPV, a Novel Pharmacologic Treatment for Persistent High-Risk HPV Infection with No FDA-Approved Therapies

    Each year, an estimated six million women in the United States acquire a high-risk HPV infection — and there are no FDA-approved treatments DARE-HPV development is backed by a $10 million U.S. government (ARPA-H)-funded contract; topline data readout expected in 2027 SAN DIEGO, May 18, 2026 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE), a purpose-driven health biotech company solely focused on closing the gap in women's health between promising science and real-world solutions, today announced the initiation of its Phase 2 clinical study of DARE-HPV, an investigational, proprietary fixed-dose formulation of lopinavir and ritonavir in a soft gel vaginal insert, designed to evalu

    5/18/26 8:00:00 AM ET
    $DARE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $DARE
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Chef Executive Officer Johnson Sabrina Martucci

    4 - Dare Bioscience, Inc. (0001401914) (Issuer)

    2/20/26 4:01:50 PM ET
    $DARE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Chef Executive Officer Johnson Sabrina Martucci

    4 - Dare Bioscience, Inc. (0001401914) (Issuer)

    2/2/26 4:06:47 PM ET
    $DARE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Chief Accounting Officer Haring-Layton Mardee

    4 - Dare Bioscience, Inc. (0001401914) (Issuer)

    2/2/26 4:05:49 PM ET
    $DARE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $DARE
    SEC Filings

    View All

    SEC Form DEFA14A filed by Dare Bioscience Inc.

    DEFA14A - Dare Bioscience, Inc. (0001401914) (Filer)

    6/1/26 5:14:59 PM ET
    $DARE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form DEFA14A filed by Dare Bioscience Inc.

    DEFA14A - Dare Bioscience, Inc. (0001401914) (Filer)

    6/1/26 8:59:59 AM ET
    $DARE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Dare Bioscience Inc. filed SEC Form 8-K: Unregistered Sales of Equity Securities

    8-K - Dare Bioscience, Inc. (0001401914) (Filer)

    5/18/26 4:25:47 PM ET
    $DARE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $DARE
    Leadership Updates

    Live Leadership Updates

    View All

    Daré Bioscience and Rosy Wellness Launch First Phase of Patient-Focused Campaign to Support DARE to PLAY™ Sildenafil Cream

    A first-of-its-kind solution for women's arousal in a proprietary topical formulation demonstrated to work where women need it most Targeted to be available by prescription in the fourth quarter of 2025 Collaboration leverages Rosy Wellness' extensive reach and community of over 250,000 women; campaign designed to drive awareness and support women with arousal concerns SAN DIEGO, July 29, 2025 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE), a biopharmaceutical company with a sole focus of closing the gap in women's health between promising science and real solutions, and Rosy Wellness, a pioneering digital platform focused on providing lifespan support for women, today announce

    7/29/25 8:00:00 AM ET
    $DARE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Daré Bioscience Announces Executive Team and Board of Directors Changes

    SAN DIEGO, Jan. 26, 2024 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE), a leader in women's health innovation, today announced changes in company management which includes the retirement of Chief Financial Officer, Lisa Walters-Hoffert, and the resignation of Chief Commercial Officer, John Fair. Both Ms. Walters-Hoffert and Mr. Fair have entered into plans with the Company to help ensure a seamless transition. Daré also announced an adjustment to the size of its Board of Directors to better reflect the Company's size following the voluntary resignations of Cheryl R. Blanchard, Ph.D. and Sophia Ononye-Onyia, Ph.D. "On behalf of the Daré team, I am so grateful to Lisa and Joh

    1/26/24 4:30:00 PM ET
    $DARE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Daré Bioscience Appoints Dr. Sophia N. Ononye-Onyia to its Board of Directors

    SAN DIEGO, April 19, 2021 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE), a leader in women's health innovation, today announced the appointment of Sophia N. Ononye-Onyia, PhD MPH MBA to its Board of Directors. "We are thrilled to add Dr. Ononye-Onyia to the Daré Board," said Sabrina Martucci Johnson, Daré's President and CEO. "Sophia has demonstrated the value of her leadership to global biopharmaceutical companies throughout her career. Her experience supporting commercialization of women's health products positions her to provide strategic guidance as our product candidates advance toward commercialization, and as we explore the variety of go-to-market partnering strategies

    4/19/21 8:00:00 AM ET
    $DARE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $DARE
    Financials

    Live finance-specific insights

    View All

    Daré Bioscience Reports First Quarter 2026 Financial Results and Provides Business Update

    Company Highlights Second Positive DSMB Review of Interim Data from Ovaprene® Phase 3 Clinical Trial, DARE to PLAY™ Anticipated Dispensing Commencement and Flora Sync LF5™ Commercial Launch Summer 2026; First Product Revenue Expected in June 2026; Call Hosted During National Women's Health Week. Conference Call and Webcast Today at 4:30 p.m. ET "We are hosting our financial results and business update call from New York, in the middle of National Women's Health Week," said Sabrina Martucci Johnson, President and Chief Executive Officer of Daré Bioscience. "Daré was built on the conviction that women's health is an investment-grade category – not a niche, not a nice-to-have, not a pink ribb

    5/14/26 4:01:00 PM ET
    $DARE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Daré Bioscience to Host First Quarter 2026 Financial Results and Company Update Conference Call and Webcast on May 14, 2026

    SAN DIEGO, May 07, 2026 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE), a purpose-driven health biotech company solely focused on closing the gap in women's health between promising science and real-world solutions, will host a conference call and live webcast at 4:30 p.m. Eastern Time on Thursday, May 14, 2026, to review its financial results for the quarter ended March 31, 2026 and to provide a company update. To access the conference call via phone, dial (646) 307-1963 or (800) 715-9871 (toll-free). The conference ID number for the call is 2531472. The live webcast can be accessed under "Presentations, Events & Webcasts" in the Investors section of the company's website at ht

    5/7/26 8:00:00 AM ET
    $DARE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Daré Bioscience Reports Full Year 2025 Financial Results and Provides Business Update

    Company Highlights Commercial Launch of DARE to PLAY™ Sildenafil Cream, Pipeline of Women's Health Solutions, and Multiple Near-Term Potential Catalysts Conference Call and Webcast Today at 4:30 p.m. ET SAN DIEGO, March 26, 2026 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE), a purpose-driven health biotech company solely focused on closing the gap in women's health between promising science and real-world solutions, today reported financial results for the year ended December 31, 2025, and provided a business update. "We are not a company that is just getting into women's health. We are a women's health biotech company – and we believe 2026 is the year investors wi

    3/26/26 4:01:00 PM ET
    $DARE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $DARE
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Dare Bioscience Inc. (Amendment)

    SC 13G/A - Dare Bioscience, Inc. (0001401914) (Subject)

    2/9/22 3:43:36 PM ET
    $DARE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Dare Bioscience Inc. (Amendment)

    SC 13G/A - Dare Bioscience, Inc. (0001401914) (Subject)

    2/9/22 3:43:35 PM ET
    $DARE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed

    SC 13G/A - Dare Bioscience, Inc. (0001401914) (Subject)

    2/12/21 5:13:06 PM ET
    $DARE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $DARE
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for XACIATO issued to DARE BIOSCIENCE INC

    Submission status for DARE BIOSCIENCE INC's drug XACIATO (ORIG-1) with active ingredient CLINDAMYCIN PHOSPHATE has changed to 'Approval' on 12/07/2021. Application Category: NDA, Application Number: 215650, Application Classification: Type 5 - New Formulation or New Manufacturer

    12/7/21 12:35:25 PM ET
    $DARE
    Biotechnology: Pharmaceutical Preparations
    Health Care